Format

Send to

Choose Destination
Psychooncology. 2018 Feb;27(2):471-476. doi: 10.1002/pon.4483. Epub 2017 Aug 4.

Cancer-related disease factors and smoking cessation treatment: Analysis of an ongoing clinical trial.

Author information

1
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
2
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Abstract

OBJECTIVE:

Smoking cessation treatment should be an important aspect of cancer care. In this study, we evaluated whether cancer-related disease factors adversely influence smoking cessation treatment.

METHODS:

Smokers with cancer (within 5 years of diagnosis, any tumor site) were recruited for an ongoing trial of varenicline for smoking cessation. Disease factors, assessed at baseline, included tumor site, cancer treatment, time since diagnosis, and health-related quality of life. Medication adherence was defined by 132 of 165 pills taken and counseling adherence was defined by 4 of 4 behavioral counseling sessions attended. Abstinence was bioverified at Week 12. Using logistic regression analysis, we assessed the relationship between disease factors and 12-week medication adherence, counseling adherence, and abstinence.

RESULTS:

Of 144 participants, 56% were medication adherent, 74% were counseling adherent, and 39% were abstinent. Health-related quality of life predicted medication adherence (OR: 1.08, 95% CI, 1.01-1.16, P = .019, d = 0.20) but not counseling adherence or 12-week abstinence. Tumor site, cancer treatment, and time since diagnosis did not predict any smoking cessation treatment outcomes.

CONCLUSIONS:

Cancer-related disease factors did not predict cancer survivors' engagement or success in smoking cessation treatment. Findings support National Comprehensive Cancer Network Clinical Practice guidelines that recommend smoking cessation treatment for all smokers with cancer, regardless of time since diagnosis.

KEYWORDS:

cancer; cancer survivors; clinical trial; oncology; smoking cessation; treatment adherence; varenicline

PMID:
28636795
PMCID:
PMC5958302
[Available on 2019-02-01]
DOI:
10.1002/pon.4483

Supplemental Content

Loading ...
Support Center